Background: In phase III TIVO-3 trial, tivozanib improved progression-free survival (PFS) compared to sorafenib for patients with metastatic renal cell carcinoma (mRCC). However, the effectiveness of this drug after exposure to other selective VEGFR agents has not yet been defined. Herein, we characterize the clinical efficacy of tivozanib in patients with mRCC previously treated with axitinib.
Methods: We identified patients from the intention to treat (ITT) population, in the TIVO-3 trial, who received treatment with axitinib before enrolment in the study and evaluated PFS, response rate (RR), and safety.
Results: Out of 350 patients, 172 (83:89, tivozanib:sorafenib) had received prior treatment with axitinib in TIVO-3. In this subgroup, PFS was 5.5 months with tivozanib and 3.7 months with sorafenib (HR 0.68). RR was 13% and 8% favoring tivozanib.
Conclusions: Tivozanib is active in the treatment of patients with mRCC who have progressed on prior therapies, including axitinib.
Trial registration: ClinicalTrials.gov NCT02627963.
Keywords: axitinib; metastatic renal cell carcinoma; sorafenib; tivozanib; vascular endothelial growth factor inhibitor.
© The Author(s) 2022. Published by Oxford University Press.